GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: GlaxoSmithKline (GSK) is conducting a Phase 3 multicenter, randomized, double-blind study titled B-Well 1 to assess the efficacy and safety of Bepirovirsen in participants with chronic Hepatitis B who are already receiving nucleos(t)ide analogue treatment. The study aims to confirm the suppression of hepatitis B virus surface antigen (HBsAg) and evaluate the safety and pharmacokinetic profile of Bepirovirsen, highlighting its potential significance in treating chronic Hepatitis B.
Intervention/Treatment: The study tests Bepirovirsen, an experimental drug, against a placebo. Bepirovirsen is intended to suppress HBsAg levels in patients, potentially offering a new treatment option for chronic Hepatitis B.
Study Design: This interventional study employs a randomized, parallel assignment model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded to treatment assignments. The primary purpose is treatment-focused, aiming to establish the efficacy and safety of Bepirovirsen.
Study Timeline: The study began on December 7, 2022, and is currently active but not recruiting. The last update was submitted on July 30, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: The progress of this study could significantly impact GSK’s stock performance and investor sentiment, especially if Bepirovirsen proves effective. Success in this study could position GSK favorably against competitors in the Hepatitis B treatment market, potentially leading to increased market share.
The study is ongoing, with further details available on the ClinicalTrials portal.